Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Individual Preparation Administrations to Raise Your Wellness Process - 2Alice Wong, founder of the Disability Visibility Project, dies at 51
- 3Dominating Your Cash: The Fundamental Manual for Overseeing Individual accounting records
- 4Europe: 4 Urban communities for a Paramount Social Experience
- 5Top Music and Dance Celebration: Which One Gets You Going?
- Well known SUVs With Low Energy Utilization In 2024
- Figure out How to Use the Experience of a Fender bender Legal counselor for Your Potential benefit
- Ancient Pompeii construction site reveals the process for creating Roman concrete
- How a niche Catholic approach to infertility treatment became a new talking point for MAHA conservatives
- Blood pressure drug recalled for possible cross-contamination
- Step by step instructions to Boost the Eco-friendliness of Your Smash 1500.
- A Manual for Nations with Extraordinary Food
- Instructions to Redo Your Kona SUV for Improved Tasteful Allure and Usefulness
- Audits of the Top Science fiction Movies This Year
